Regen BioPharma Inc. is a publicly traded biotechnology company that trades under the symbol RGBP on the OTC Bulletin Board. Regen is focused on identifying undervalued regenerative medicine applications in the stem cell/immunotherapy space and rapidly advancing these technologies through pre-clinical and Phase I/II clinical trials. Currently the Company is developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).
Regen BioPharma is a biotechnology company focused on stem cell and immunotherapies for specialty niche treatments.
Currently we are focused on aplastic anemia, gene silencing and small molecule development.
Complete listing, click "READ MORE".
December 15, 2015 SOURCE: REGEN BIOPHARMA INC. Regen BioPharma, Inc. Receives FDA Clearance to Initiate Clinical Trial of HemaXellerate. Company to initiate Phase I Clinical Trial for IMmune Modulatory Personalized Cell Therapy in Treatment of Aplastic Anemia.
Regen BioPharma Inc. trades under the symbol RGBP on the OTC Bulletin Board and OTC PINK markets. Regen is a biotechnology company focused on...
Presentations At International Conferences
List of Conferences that Regen BioPharma Inc. has made presentations.
Visit us on Twitter
Regen BioPharma :: Fast Forwarding Stem Cell Medicine
Copyright Regen BioPharma, Inc. 2017